Although once regarded for their potential in cancer treatments (Vigushin and Coombes, 2002), HDAC inhibitors are now regarded as potential therapeutic targets in AD patients (Xu et al., 2011) with a wide array of effects (Figure 2). The gene discussed is HDAC9; the disease is Alzheimer disease.